Organization (Industry)
BrosMed Medical Co., Ltd. (China)
ClinicalTrials.gov lists BrosMed Medical Co., Ltd. (China) as lead sponsor of 13 trials. It has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BrosMed Medical Co., Ltd. (China): 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (13)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Artery Disease | 10 |
| Coronary Disease | 10 |
| Arteriovenous Fistula | 1 |
| Arteriovenous Malformations | 1 |
| Atherosclerosis | 1 |
Showing 5 of 13 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 1 |
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline) | Plaque, Atherosclerotic | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 2 hit target (n=2) | 2 of 2 on time (n=2) |
Journals published in (1)
| Journal | Publications |
|---|---|
| Journal of thoracic disease | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 3 | 3 | 2025-09-02 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Hermes NC PTA Balloon Dilatation Catheter The balloon dilatation catheter is intended to dilate stenoses in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent dilatation post-deployment in the peripheral vasculature. | Class II | 2018-12-14 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2026-03-27 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| BROSMED MEDICAL CO.,LTD | Dongguan Guangdong, CN | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| CCRF Inc., Beijing, China | Co sponsors trial with | 1 |
Latest dated events (24)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-27 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-09-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 24 events.
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| DLD | Trial sponsor | Named in trial exclusion criteria |
| LAD1 | Trial sponsor | Named in trial exclusion criteria |
| DLD | Trial sponsor | Mentioned in trial text |
| LAD1 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.